Literature DB >> 10945614

Nuclear factor kappaB subunits induce epithelial cell growth arrest.

C S Seitz1, H Deng, K Hinata, Q Lin, P A Khavari.   

Abstract

Nuclear factor kappaB (NF-kappaB) gene-regulatory proteins play important roles in inflammation, neoplasia, and programmed cell death. Recently, blockade of NF-kappaB function has been shown to result in epithelial hyperplasia, suggesting a potential role for NF-kappaB in negative growth regulation. We expressed active NF-kappaB subunits in normal epithelial cells and found that NF-kappaB profoundly inhibits cell cycle progression. This growth inhibition is resistant to mitogenic stimuli and is accompanied by other features of irreversible growth arrest. NF-kappaB-triggered cell cycle arrest is also associated with selective induction of the cyclin-dependent kinase inhibitor p21CiP1, with overexpression of p21(Cip1) alone inducing findings similar to those seen with NF-kappaB in vitro. An active NF-kappaB subunit expressed in the epidermis of p21(CiP1-/- mice, however, displays only partial growth-inhibitory effects, suggesting that full NF-kappaB growth inhibition is only partially p21(Cip1) dependent in this setting. These data indicate that NF-kappaB can trigger cell cycle arrest in epithelial cells in association with selective induction of a cell cycle inhibitor.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10945614

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  40 in total

1.  NF-κB in Aging and Disease.

Authors:  Jeremy S Tilstra; Cheryl L Clauson; Laura J Niedernhofer; Paul D Robbins
Journal:  Aging Dis       Date:  2011-12-02       Impact factor: 6.745

2.  Alternative nuclear functions for NF-κB family members.

Authors:  Lluís Espinosa; Anna Bigas; Maria Carmen Mulero
Journal:  Am J Cancer Res       Date:  2011-02-16       Impact factor: 6.166

3.  HIV-1 Vpr protein activates the NF-κB pathway to promote G2/M cell cycle arrest.

Authors:  Zhibin Liang; Ruikang Liu; Yongquan Lin; Chen Liang; Juan Tan; Wentao Qiao
Journal:  Virol Sin       Date:  2015-12-14       Impact factor: 4.327

Review 4.  Multiple functions of the integrin alpha6beta4 in epidermal homeostasis and tumorigenesis.

Authors:  Kevin Wilhelmsen; Sandy H M Litjens; Arnoud Sonnenberg
Journal:  Mol Cell Biol       Date:  2006-04       Impact factor: 4.272

5.  c-Rel downregulation affects cell cycle progression of human keratinocytes.

Authors:  Verena N Lorenz; Michael P Schön; Cornelia S Seitz
Journal:  J Invest Dermatol       Date:  2013-07-26       Impact factor: 8.551

6.  Sustained NF-kappaB activation produces a short-term cell proliferation block in conjunction with repressing effectors of cell cycle progression controlled by E2F or FoxM1.

Authors:  Marianna Penzo; Paul E Massa; Eleonora Olivotto; Francesca Bianchi; Rosa Maria Borzi; Adedayo Hanidu; Xiang Li; Jun Li; Kenneth B Marcu
Journal:  J Cell Physiol       Date:  2009-01       Impact factor: 6.384

7.  Activation of the NF-kappaB pathway in human cytomegalovirus-infected cells is necessary for efficient transactivation of the major immediate-early promoter.

Authors:  Ian B DeMeritt; Liesl E Milford; Andrew D Yurochko
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

8.  TAp63 is a transcriptional target of NF-kappaB.

Authors:  Junfeng Wu; Johann Bergholz; Jinin Lu; Gail E Sonenshein; Zhi-Xiong Jim Xiao
Journal:  J Cell Biochem       Date:  2010-03-01       Impact factor: 4.429

9.  Expression of CYLD and NF-kappaB in human cholesteatoma epithelium.

Authors:  Jae Yong Byun; Tae Young Yune; Jee Youn Lee; Seung Geun Yeo; Moon Suh Park
Journal:  Mediators Inflamm       Date:  2010-04-21       Impact factor: 4.711

10.  Epstein-Barr virus-encoded EBNA1 inhibits the canonical NF-kappaB pathway in carcinoma cells by inhibiting IKK phosphorylation.

Authors:  Robert Valentine; Christopher W Dawson; Chunfang Hu; Khilan M Shah; Thomas J Owen; Kathryn L Date; Sonia P Maia; Jianyong Shao; John R Arrand; Lawrence S Young; John D O'Neil
Journal:  Mol Cancer       Date:  2010-01-05       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.